DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > University Hospital > Articles in academic journal >

In vivo efficacy of KRP-109, a novel elastase inhibitor, in a murine model of severe pneumococcal pneumonia.

File Description SizeFormat
PPT24_660.pdf935.23 kBAdobe PDFView/Open

Title: In vivo efficacy of KRP-109, a novel elastase inhibitor, in a murine model of severe pneumococcal pneumonia.
Authors: Yamada, Koichi / Yanagihara, Katsunori / Araki, Nobuko / Harada, Yosuke / Morinaga, Yoshitomo / Izumikawa, Koichi / Kakeya, Hiroshi / Yamamoto, Yoshihiro / Hasegawa, Hiroo / Kohno, Shigeru / Kamihira, Shimeru
Issue Date: Dec-2011
Publisher: Elsevier Ltd.
Citation: Pulmonary Pharmacology & Therapeutics, 24(6), pp.660-665; 2011
Abstract: KRP-109 is a novel specific inhibitor of neutrophil elastase (NE). Various studies suggest that NE inhibitors reduce lung injury associated with systemic inflammatory response syndrome (SIRS). In this study, the efficacy of KRP-109 was examined using a murine model of severe pneumonia induced by Streptococcus pneumoniae (S. pneumoniae). Female mice (CBA/J, aged 5 weeks) were inoculated intranasally with penicillin-susceptible S. pneumoniae (ATCC49619 strain, 2.5 × 10(8) CFU/mouse). KRP-109 (30 or 50 mg/kg) or physiological saline as a control was administered intraperitoneally every 8 h beginning at 8 h after inoculation, and survival rate was evaluated over 7 days. Histopathological and bacteriological analyses of the lung, and bronchoalveolar lavage were performed at 48 h post-infection. The mice treated with KRP-109 (KRP-109 mice) tended to have higher survival rate than those given saline. The lung tissues of the KRP-109 mice had few neutrophils in the alveolar walls and less inflammation. Furthermore, KRP-109 decreased significantly total cell and neutrophil counts, and cytokine levels (interleukin 1β and macrophage inflammatory protein 2) in bronchoalveolar lavage fluid. Viable bacterial numbers in lung were not influenced by treatment of KRP-109. The present results indicate that KRP-109 reduces lung inflammation in a murine model, and that KRP-109 may be useful for the treatment of patients with severe pneumonia.
Keywords: Immunomodulation therapy / Neutrophil elastase / Streptococcus pneumonia
URI: http://hdl.handle.net/10069/26864
ISSN: 10945539
DOI: 10.1016/j.pupt.2011.08.001
PubMed ID: 21864700
Relational Links: http://hdl.handle.net/10069/29737
Rights: Copyright © 2011 Elsevier Ltd. All rights reserved.
Type: Journal Article
Text Version: author
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/26864

All items in NAOSITE are protected by copyright, with all rights reserved.


Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace